Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional)

This grant supports translating genome editing and other biologic therapies for Alzheimer's Disease-Related Dementias across the full translational pipeline. It funds work such as therapeutic lead optimization, drug product development, IND-enabling studies, early clinical evaluation, safety pharmacology, toxicology, scalable manufacturing, and formulation aligned with regulatory expectations.

Amount: up to $2.5M
Type: Grant

Key facts

Key facts for Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional)
Amount	up to $2.5M
Issuer	National Institutes of Health
Who can apply	Small businesses, companies, universities and 7 more
Sectors	HealthTech
Deadline	Closes 10 Oct 2028

Unlock application details

See all eligibility criteria, required documents and the official application link. Free account, no card.

Update history

Source: grants.gov ↗

Source checked 3 days ago

3 days agoagentImported from the official source

Opportunities with the same funding type or region
European Degree Exploratory Action		Closes 18 Feb 2027
Cooperative Agreement for affiliated Partner with Alaska Cooperative Ecosystem Studies Unit	up to $234,460	Closes 07 Dec 2026
Cooperative Agreement for affiliated Partner with Colorado Plateau Cooperative Ecosystem Studies Unit	up to $150,000	Closes 07 Dec 2026